Eli Lilly & Co stock kpis
Want to see LLY full AI Analyst Report?
Revenue by Segment
In Q3 2026, Eli Lilly & Co reported revenue by segment of $154.00M (Other), $444.00M (Neuroscience), $2.60B (Oncology), $1.44B (Immunology) and $19.76B (Cardiometabolic).
Splits sales by business lines or therapy areas to reveal whether Lilly’s growth is driven by a few blockbuster drugs or a diversified portfolio. Helps investors assess product concentration risk, the impact of new launches, and which segments are likely to sustain revenue and profit expansion.
Cardiometabolic has become the dominant growth engine, driving a structural shift in Lilly’s revenue mix and underpinning the company’s guidance and margin upgrade; Oncology and Immunology provide steady, compounding support rather than the spike, while Neuroscience and Other are comparatively muted. Q2 commercial scale (Mounjaro/Zepbound) validates the upside, but monitor near‑term risks — U.S. price/rebate pressure, launch noise (Foundayo) and retatrutide regulatory timing — that could slow percentage growth or compress net pricing despite rising volume.
LLY Revenue by Segment
| Period | Other | Cardiovascular | Neuroscience | Oncology | Immunology | Animal Health | Cardiometabolic |
|---|---|---|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $154.00M | $0.00 | $444.00M | $2.60B | $1.44B | $0.00 | $19.76B |
| Q2 2026Jun 30, 2026 | $205.00M | $0.00 | $429.00M | $2.57B | $1.42B | $0.00 | $18.35B |
| Q1 2026Mar 31, 2026 | $187.00M | $0.00 | $382.00M | $2.27B | $1.20B | $0.00 | $15.76B |
| Q4 2025Dec 31, 2025 | $191.40M | $0.00 | $459.20M | $2.61B | $1.54B | $0.00 | $14.49B |
| Q3 2025Sep 30, 2025 | $337.20M | $0.00 | $315.70M | $2.41B | $1.36B | $0.00 | $13.18B |
| Q2 2025Jun 30, 2025 | $201.50M | $0.00 | $344.00M | $2.41B | $1.26B | $0.00 | $11.34B |
| Q1 2025Mar 31, 2025 | $212.90M | $0.00 | $272.10M | $1.95B | $1.09B | $0.00 | $9.21B |
| Q4 2024Dec 31, 2024 | $190.60M | $0.00 | $393.10M | $2.55B | $1.29B | $0.00 | $9.11B |
| Q3 2024Sep 30, 2024 | $262.80M | $0.00 | $351.80M | $2.23B | $1.19B | $0.00 | $7.41B |
| Q2 2024Jun 30, 2024 | $207.60M | $0.00 | $339.50M | $2.16B | $1.08B | $0.00 | $7.51B |
| Q1 2024Mar 31, 2024 | $241.90M | $0.00 | $389.10M | $1.81B | $834.00M | $0.00 | $5.49B |
| Q4 2023Dec 31, 2023 | $256.20M | $0.00 | $362.70M | $1.88B | $1.10B | $0.00 | $5.75B |
| Q3 2023Sep 30, 2023 | $276.10M | $0.00 | $1.77B | $1.75B | $986.90M | $0.00 | $4.72B |
| Q2 2023Jun 30, 2023 | $314.60M | $0.00 | $387.20M | $1.67B | $928.50M | $0.00 | $5.01B |
| Q1 2023Mar 31, 2023 | $275.30M | $0.00 | $360.50M | $1.36B | $777.80M | $0.00 | $4.19B |
| Q4 2022Dec 31, 2022 | $355.90M | $0.00 | $385.30M | $1.65B | $933.60M | $0.00 | $3.98B |
| Q3 2022Sep 30, 2022 | $746.00M | $0.00 | $373.20M | $1.29B | $866.40M | $0.00 | $3.66B |
| Q2 2022Jun 30, 2022 | $494.70M | $0.00 | $389.90M | $1.37B | $796.50M | $0.00 | $3.44B |
| Q1 2022Mar 31, 2022 | $1.92B | $0.00 | $397.70M | $1.35B | $748.10M | $0.00 | $3.39B |
| Q4 2021Dec 31, 2021 | $1.54B | $0.00 | $470.60M | $1.41B | $956.50M | $0.00 | $3.63B |
| Q3 2021Sep 30, 2021 | $637.70M | $0.00 | $450.20M | $1.41B | $1.00B | $0.00 | $3.27B |
| Q2 2021Jun 30, 2021 | $712.90M | $0.00 | $512.20M | $1.55B | $785.40M | $0.00 | $3.18B |
| Q1 2021Mar 31, 2021 | $1.24B | $0.00 | $465.40M | $1.37B | $613.90M | $0.00 | $3.11B |
| Q4 2020Dec 31, 2020 | $1.45B | $0.00 | $474.60M | $1.52B | $700.70M | $0.00 | $3.30B |
| Q3 2020Sep 30, 2020 | $526.40M | $0.00 | $470.70M | $1.33B | $627.10M | $0.00 | $2.78B |
| Q2 2020Jun 30, 2020 | $481.00M | $0.00 | $422.50M | $1.27B | $548.30M | $0.00 | $2.78B |
| Q1 2020Mar 31, 2020 | $640.10M | $0.00 | $463.50M | $1.20B | $585.50M | $0.00 | $2.97B |
| Q4 2019Dec 31, 2019 | $326.00M | $0.00 | $450.30M | $1.26B | $547.90M | $0.00 | $3.53B |
| Q3 2019Sep 30, 2019 | $303.50M | $0.00 | $426.70M | $1.15B | $454.60M | $0.00 | $3.14B |
| Q2 2019Jun 30, 2019 | $323.50M | $0.00 | $452.70M | $1.20B | $456.10M | $0.00 | $3.21B |
| Q1 2019Mar 31, 2019 | $421.60M | $0.00 | $393.10M | $1.01B | $334.70M | $0.00 | $2.93B |
| Q4 2018Dec 31, 2018 | $46.40M | $408.60M | $449.80M | $1.13B | $377.10M | $816.50M | $3.21B |
| Q3 2018Sep 30, 2018 | $56.60M | $583.80M | $427.20M | $1.06B | $319.50M | $772.70M | $2.84B |
| Q2 2018Jun 30, 2018 | $69.50M | $693.00M | $471.00M | $1.11B | $264.70M | $792.10M | $2.95B |
| Q1 2018Mar 31, 2018 | $70.50M | $561.50M | $472.70M | $956.60M | $178.70M | $761.30M | $2.97B |
| Q4 2017Dec 31, 2017 | $56.80M | $698.70M | $497.30M | $1.01B | $195.50M | $790.90M | $2.91B |
| Q3 2017Sep 30, 2017 | $61.00M | $662.90M | $507.70M | $957.60M | $167.60M | $740.60M | $2.56B |
| Q2 2017Jun 30, 2017 | $49.60M | $812.40M | $586.70M | $955.90M | $143.50M | $784.80M | $2.49B |
| Q1 2017Mar 31, 2017 | $73.80M | $697.20M | $579.30M | $887.00M | $98.50M | $769.40M | $2.12B |
| Q4 2016Dec 31, 2016 | $39.30M | $870.40M | $650.40M | $909.50M | $61.30M | $837.60M | $2.39B |
| Q3 2016Sep 30, 2016 | $47.90M | $773.50M | $708.50M | $947.30M | $32.50M | $706.20M | $1.98B |
| Q2 2016Jun 30, 2016 | $51.80M | $827.30M | $717.70M | $970.50M | $19.30M | $859.80M | $1.96B |
| Q1 2016Mar 31, 2016 | $61.40M | $754.20M | $643.70M | $894.50M | $0.00 | $754.60M | $1.76B |

